← FDA DRUG APPROVALS
FDA ANDA · ANDA212219
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Sponsor: BAXTER HLTHCARE CORP
APPLICATION
ANDA212219
TYPE
ANDA
ORIGINAL APPROVAL
2022-10-19
LATEST ACTION
2022-10-19
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE, LIPOSOMAL
MARKETING STATUS
Prescription
Products
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)Prescription
DOXORUBICIN HYDROCHLORIDE 50MG/25ML (2MG/ML) · INJECTABLE, LIPOSOMAL · INJECTION
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)Prescription
DOXORUBICIN HYDROCHLORIDE 20MG/10ML (2MG/ML) · INJECTABLE, LIPOSOMAL · INJECTION
Approval history
2022-10-19UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.